NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis $2.70 -0.06 (-2.17%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Lexaria Bioscience Stock (NASDAQ:LEXX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$2.60▼$2.8550-Day Range$2.75▼$3.9152-Week Range$1.08▼$6.85Volume164,391 shsAverage Volume277,712 shsMarket Capitalization$34.79 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company OverviewLexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Lexaria Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks48th Percentile Overall ScoreLEXX MarketRank™: Lexaria Bioscience scored higher than 48% of companies evaluated by MarketBeat, and ranked 603rd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLexaria Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexaria Bioscience has received no research coverage in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lexaria Bioscience are expected to grow in the coming year, from ($0.42) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -6.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 8.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lexaria Bioscience's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.13% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently decreased by 2.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.13% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently decreased by 2.02%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have sold 105.03% more of their company's stock than they have bought. Specifically, they have bought $5,008.00 in company stock and sold $10,268.00 in company stock.Percentage Held by InsidersOnly 7.61% of the stock of Lexaria Bioscience is held by insiders.Percentage Held by InstitutionsOnly 13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address LEXX Stock News HeadlinesTinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 ProgramSeptember 13, 2024 | msn.comLexaria Bioscience (NASDAQ: LEXX) Shares Letter from Outgoing CEOSeptember 10, 2024 | theglobeandmail.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Lexaria (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) LiraglutideSeptember 8, 2024 | theglobeandmail.comLexaria (NASDAQ: LEXX) Announces Agreement to Evaluate DehydraTECH(TM) in Pre-Clinical SettingSeptember 5, 2024 | theglobeandmail.comLexaria Bioscience (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 31, 2024 | theglobeandmail.comHempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test ResultsAugust 29, 2024 | msn.comLexaria Bioscience Corp.: First Results from Lexaria's Second GLP-1 Human Pilot StudyAugust 28, 2024 | finanznachrichten.deSee More Headlines LEXX Stock Analysis - Frequently Asked Questions How have LEXX shares performed this year? Lexaria Bioscience's stock was trading at $1.25 at the beginning of the year. Since then, LEXX shares have increased by 116.0% and is now trading at $2.70. View the best growth stocks for 2024 here. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR). Company Calendar Today10/23/2024Next Earnings (Estimated)11/19/2024Fiscal Year End8/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEXX CUSIPN/A CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$12.00 Low Stock Price Target$10.00 Potential Upside/Downside+307.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,660,000.00 Net MarginsN/A Pretax Margin-1,292.04% Return on Equity-88.39% Return on Assets-84.05% Debt Debt-to-Equity RatioN/A Current Ratio58.27 Quick Ratio58.27 Sales & Book Value Annual Sales$411,019.00 Price / Sales84.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book8.18Miscellaneous Outstanding Shares12,886,000Free Float14,607,000Market Cap$34.79 million OptionableNot Optionable Beta0.97 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:LEXX) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.